Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Progesterone Resistance 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

pembrolizumab 602Cyclophosphamide 545Magnetic Resonance Spectroscopy 524Radiotherapy 513Specimen Handling 506Nivolumab 412Cisplatin 380Carboplatin 368Biopsy 306Blood Specimen Collection 302Radiosurgery 290Paclitaxel 280Surveys and Questionnaires 270Gemcitabine 270Standard of Care 267Drug Therapy 263Dexamethasone 263fludarabine 262Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 198Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 184Doxorubicin 179Etoposide 176atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cyproterone acetate, ethinyl estradiol drug combination × 1 year × Clear all
NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Fudan University

Phase 2/3 Recruiting
80 enrolled
Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡